Blog
RSS FeedPosted by Michael Wonder on 01 Sep 2019
ICER posts draft scoping document for the assessment of treatments for sickle cell disease
30 August 2019 - Document open to public comment until 20 September 2019. ...
Posted by Michael Wonder on 15 Aug 2019
ICER's value framework and patient feedback: Q&A with Steve Pearson
15 August 2019 - ICER invites all patient organizations and the general public to attend a webinar to learn more ...
Posted by Michael Wonder on 10 Aug 2019
ICER to assess treatments for sickle cell disease
9 August 2019 - Report will be subject of New England CEPAC meeting in March 2020; open Input now being ...
Posted by Michael Wonder on 06 Aug 2019
A watchdog group sets aside emotions to assess drugs’ value. Patients say their lives are more than a number.
2 August 2019 - Health economists walk a precarious tightrope: their analyses are quantitative and, presumably, emotion-free. But health care ...
Posted by Michael Wonder on 24 Jul 2019
Patients, backed by ‘dark money’ group, get ready to debate Duchenne drug prices. It will not be boring.
24 July 2019 - Meetings of the Institute for Clinical and Economic Review don’t usually get one’s heart pumping. ...
Posted by Michael Wonder on 24 Jul 2019
ICER releases draft evidence report on additive cardiovascular disease therapies
24 July 2019 - Public comment period now open until 20 August 2019; requests to make oral comment during public ...
Posted by Michael Wonder on 12 Jul 2019
Aimmune statement on ICER final report on AR101 for peanut allergy
11 July 2019 - Exclusion of long-term desensitization and patient quality-of-life data by ICER fails to recognize the full value AR101 ...
Posted by Michael Wonder on 11 Jul 2019
ICER publishes evidence report on treatments for Duchenne muscular dystrophy
11 July 2019 - No price can be suggested as a fair value-based price for eteplirsen or golodirsen because no persuasive ...
Posted by Michael Wonder on 10 Jul 2019
ICER's final report on peanut allergy treatments: clinical evidence does not yet demonstrate that long-term benefits of desensitisation outweigh short-term risks
10 July 2019 - Independent appraisal committee highlights importance of non-clinical benefits and contextual considerations when evaluating AR101 and Viaskin Peanut. ...
Posted by Michael Wonder on 29 Jun 2019
ICER posts draft scoping document for the assessment of treatments for acute migraine
28 June 2019 - Document open to public comment until 19 July 2019 ...
Posted by Michael Wonder on 24 Jun 2019
It’s Pioneer Institute vs. ICER: drug-pricing watchdog comes under fire for a ‘one-size-fits-all’ approach
24 June 2019 - An influential Boston-based watchdog group uses a “one-size-fits-all” approach to judge a fair price for prescription ...
Posted by Michael Wonder on 21 Jun 2019
U.S. group says Novartis MS drug price out of line with benefit
21 June 2019 - A U.S. group that reviews the value of medicines issued a critical report on Novartis’s new ...
Posted by Michael Wonder on 20 Jun 2019
ICER issues final report and policy recommendations on esketamine for treatment-resistant depression
20 June 2019 - Independent appraisal committee votes that evidence is adequate to demonstrate clinical benefits of esketamine versus placebo, ...
Posted by Michael Wonder on 20 Jun 2019
Boston drug pricing watchdog group has pharma companies’ attention
19 June 2019 - His adversaries call him a shill for health insurers, a bloodless bean counter who would rather ...
Posted by Michael Wonder on 15 Jun 2019
Asthma and Allergy Foundation of America elevates patient voice in ICER review of new peanut allergy treatments
14 June 2019 - On June 11 in Oakland, CA the Institute for Clinical and Economic Review and its California Technology ...